Actively Recruiting

Phase Not Applicable
Age: 18Years - 50Years
All Genders
NCT06207162

Longitudinal Neural Fingerprinting of Opioid-use Trajectories

Led by Yale University · Updated on 2025-08-29

10

Participants Needed

1

Research Sites

64 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

N

National Institute on Drug Abuse (NIDA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This project aims to collect a densely sampled neuroimaging dataset among individuals receiving medications for opioid use disorder (MOUD). MOUD is multiphasic, comprised of medication induction, stabilization, ongoing treatment, and eventual dis-continuation phases. However, with a few small exceptions, existing neuroimaging efforts are almost exclusively single time-point assessments which, by definition, fail to capture these clinically relevant transitions and thus also do not capture individual risk and resilience trajectories. The investigators innovation, the characterization of neurocomputational trajectories during clinically relevant phases of MOUD treatment, will provide unprecedented mechanistic insight into the neurobiological basis of recovery. Once characterized, such trajectories may be used in the identification of specific therapeutic windows for additional intervention (e.g., times of increased neural plasticity) and in the design of novel tailored interventions based on known brain mechanisms (e.g., behavioral therapy, neurostimulation, neurofeedback).

CONDITIONS

Official Title

Longitudinal Neural Fingerprinting of Opioid-use Trajectories

Who Can Participate

Age: 18Years - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Within the first 6 months of methadone treatment for opioid use disorder and on a stable dose of methadone
  • Eligible for MRI scanning
  • Willing to commit to longitudinal study visits
Not Eligible

You will not qualify if you...

  • Current psychosis, mania, or suicidal ideation with intent
  • Current severe substance-use disorders excluding nicotine and opioids
  • Current intoxication or acute withdrawal preventing participation
  • Severe cognitive impairment or intellectual disability
  • History of neurological disease including seizures or epilepsy
  • Head trauma with loss of consciousness over 30 minutes
  • Organ dysfunction or unstable medical conditions affecting brain function or study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

MRRC at The Anlyan Center

New Haven, Connecticut, United States, 06520

Actively Recruiting

Loading map...

Research Team

S

Sarah Yip, PhD, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here